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Background: Oncolytic viruses represent a novel form of cancer immunotherapy. Vaccinia viruses encoding human
T cell co-stimulatory molecules have demonstrated clinical activity in phase I clinical trials in patients with advanced
melanoma. However, predictive biomarkers of therapeutic response have not yet been identified.
Methods: A customized microarray was performed to identify changes in peripheral blood mononuclear cell
(PBMC) gene expression upon exposure to recombinant oncolytic vaccinia viruses. Up-regulated and down-
regulated genes were identified and selected for further analysis using PBMC samples from normal donors and
oncolytic virus-treated patients before and after viral injection. Quantitative PCR and flow cytometry of defined T cell
subsets was performed to evaluate expression patterns and clinical correlations.
Results: The microarray identified 301 genes that were up-regulated and 960 genes that were down-regulated in T
cells after exposure to oncolytic vaccinia virus. The B7.1 gene was highly up-regulated and the immunoglobulin-like
transcript 2 (ILT2) gene was highly down-regulated by vaccinia-B7.1, which was consistent with the known inverse
regulation of these two genes. We observed an inverse association between ILT2 expression in the tumor micro-
environment and clinical response and further identified ILT2 as a marker of regulatory CD4+ and suppressor CD8+
T cell responses and whose down-regulation was predictive of therapeutic responses in patients treated with onco-
lytic virus immunotherapy.
Conclusions: ILT2 is a new putative biomarker of T cell and clinical response in patients treated with oncolytic
vaccinia virus immunotherapy. Further confirmation of ILT2 as a biomarker requires prospective validation in a
larger series of clinical trials.
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vaccinesBackground
Oncolytic viruses mediate tumor regression through se-
lective replication in and lysis of tumor cells and induc-
tion of systemic anti-tumor immunity [1]. Vaccinia
viruses are members of the poxviridae family of DNA vi-
ruses and have been used to effectively prevent smallpox in
humans, as a recombinant vector for gene delivery and sys-
temic vaccination, and as an oncolytic immunotherapy [2].* Correspondence: howard.kaufman@rutgers.edu
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stated.We have previously demonstrated that administering
recombinant vaccinia viruses encoding T cell co-
stimulatory molecules by intra-tumoral injection in-
duces objective clinical responses and improved local
and systemic anti-tumor immunity in patients with
metastatic melanoma [3,4]. In a phase I clinical trial
using recombinant vaccinia viruses encoding human
B7.1 (rV-B7.1), three of 12 patients demonstrated dis-
ease control with one patient achieving a durable re-
sponse lasting more than 59 months, which was
associated with the emergence of melanoma-specifictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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In a second phase I clinical trial using recombinant vaccinia
viruses encoding a triad of T cell co-stimulatory molecules
including B7.1, ICAM-1, and LFA-3 (rV-TRICOM),
a 30.7% objective response rate was demonstrated with one
patient achieving a durable complete response [4]. Ideally, a
predictive biomarker to identify patients more likely to re-
spond to treatment or to identify patients likely to benefit
from continued therapy is vital.
In order to identify putative biomarkers of response to
oncolytic vaccinia virus immunotherapy, we developed a
customized microarray focused on gene expression
changes in T cells following exposure to rV-infected au-
tologous dendritic cells. This strategy was undertaken
because of the previously established relationship be-
tween therapeutic responses and T cell responses ob-
served in early phase clinical trials [3,5]. We identified
1,261 genes significantly modulated in T cells exposed to
vaccinia virus, and from those we chose to focus on one
biomarker, immunoglobulin-like transcript 2 (ILT2) be-
cause of its known function in suppressing T cell re-














































Figure 1 Genes differentially expressed in healthy donor PBMCs after
rV-B7.1 vaccine for 12 hours and gene expression profiles were analyzed us
Ten immune-related genes of interest showing high degrees of up-regulat
down-regulation are listed along with their intensity ratios. All genes testeddue to its expression on the surface of T cells. The data
reported here support the potential role of ILT2 as a bio-
marker of response to oncolytic vaccinia virus immuno-
therapy in patients with melanoma. Larger prospective
clinical trials will be needed to further validate ILT2 as a
general predictive biomarker for responses using oncoly-
tic virus treatment and possibly other forms of tumor
immunotherapy.
Results
Biomarker discovery for oncolytic vaccinia virus
immunotherapy responses
To identify putative biomarkers predictive of response
with oncolytic vaccinia virus immunotherapy, healthy
donor (n = 6) PBMCs were treated with rV-B7.1 vaccine
for 12 hours and gene expression profiles were analyzed
by gene microarray. The analysis identified 301 up-
regulated and 960 down-regulated genes following treat-
ment (Additional file 1: Table S1 and Additional file 2:
Table S2). Ten highly up-regulated and ten highly down-
regulated immune-related genes of interest are listed in
Figure 1. The majority of the highly up-regulated genesn-regulated immune-related genes*
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are listed in Additional files 1 and 2. *P < 0.05.
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(CD80) consistent with the potent interferon-gamma re-
sponse elicited by vaccinia viruses [6]. We chose to focus
on ILT2 because: 1) ILT2 gene expression was signifi-
cantly down-regulated by rV-B7.1 among the 960 identi-
fied down-regulated genes; 2) ILT2-related factors, such
as ILT3, have been associated with inhibiting immune-
mediated tumor rejection [7]; 3) ILT gene expression is
inversely regulated by B7.1; and 4) ILT2 is known to be
an inhibitor of T cell activation [8]. Thus, we hypothe-
sized that ILT2 could be a potential biomarker and/or
target for immunotherapy.
Gene expression profiles from metastatic melanoma
lesions were obtained from fine needle aspiration sam-
ples before the first and four weeks after the third intra-
tumoral rV-B7.1 vaccination from five patients (two re-
sponders and three non-responders) and analyzed by
customized gene microarray. The resultant heat map is
shown in Figure 2A. We identified 55 genes that were
up-regulated and 37 genes that were down-regulated fol-
lowing oncolytic virus injection (Additional file 3: Table
S3). Among these genes, ILT2 was down-regulated in
the tumor of clinically responding patients and up-
regulated in non-responders (Figure 2B), suggesting that
ILT2 may be a predictive biomarker of response to onco-
























































































Figure 2 Genes differentially expressed in patients’ tumor microenvir
profiles from metastatic melanoma lesions were obtained from fine needle
after (post) the third intra-tumoral rV-B7.1 vaccination and analyzed using a
(A) The resultant heat map is shown. (B) Fold change (post / pre) of ILT2 g
and non-responders (n = 3). PD = progressive disease, SD = stable disease,Detection of ILT2 expression on T cells of melanoma
patients
In order to determine the baseline level of ILT2 expres-
sion in patients with melanoma, we evaluated ILT2 ex-
pression by flow cytometry in healthy donors and
patients with metastatic melanoma. Since ILT2 is com-
monly expressed on T cells, we focused our analysis on
ILT2 expression on total T cell populations and T cell
regulatory/suppressor subsets. First, we evaluated the
frequency of CD4+FoxP3+ Tregs in melanoma patients
and healthy donors, and as previously reported [9], we
found an increase in Tregs in the melanoma patients
compared to healthy donors (n = 21 and 19, respect-
ively); P = 0.007; Figure 3A). We next evaluated the
mean percentage of CD4+ and CD8+ T cells expressing
ILT2 and found it to be significantly elevated in meta-
static melanoma patients compared to healthy donors
(n = 11 and 10-11, respectively; P = 0.002 and P = 0.0009,
respectively; Figure 3B and C). We also found that the
frequency of CD4+FoxP3+ Tregs expressing ILT2 was
higher in patients with melanoma compared to healthy
donors (n = 11 and 11, respectively; P = 0.003; Figure 3D).
These data demonstrate that baseline levels of ILT2 can
be identified in peripheral T cells and that patients with
metastatic melanoma have significantly higher frequen-











onment before and after rV-B7.1 treatment. Gene expression
aspiration (FNA) samples (n = 5) before (pre) the first and four weeks
customized 32x24x23 (~17,000 spot) human cDNA microarray.
ene expression in tumor FNAs from (A) shown for responders (n = 2)
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Figure 3 ILT2 expression by T cell populations of healthy donors and metastatic melanoma patients. (A) Evaluation by flow cytometry of
frequency of peripheral blood cells expressing FoxP3 among CD4+ T cells (healthy donors n = 19, melanoma patients n = 21) and (B-D) ILT2
among (B) CD4+ T cells (healthy donors n = 11, melanoma patients n = 11), (C) CD8+ T cells (healthy donors n = 10, melanoma patients n = 11),
and (D) CD4+FoxP3+ T cells (healthy donors n = 11, melanoma donors n = 11).
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vaccinia virus-treated patients
First, we analyzed if there were any differences in ILT2
expression on CD4+, CD8+, Treg or Ts cells among all
patients (responders and non-responders) before and
after intra-tumoral treatment with oncolytic vaccinia
and found no significant differences (Figure 4). Next, we
compared ILT2 expression in the various T cell subsets
in PBMCs from clinical responder and non-responder
patients. Figure 5 displays the data for CD4+ T cells in
which we observed no difference in baseline (pre-treat-
ment) Tregs (P = 0.130) but did see a significantly de-
creased frequency of post-treatment Tregs in responding
versus non-responding patients (P = 0.039, Figure 5A).
We saw a similar pattern in CD4+ILT2+ T cells with no
difference prior to treatment across all patients (P =
0.294), but a significantly lower frequency of CD4+ILT2+
T cells was detected following treatment in responding
versus non-responding patients (P = 0.048; Figure 5B).
Since ILT2 could potentially be a previously unrecognized
marker of Treg cells we also stained CD4+ T cells for both
FoxP3 and ILT2. While there were no differences in
baseline CD4+FoxP3 + ILT2+ T cells in all patients (P =
0.165), the responding patients demonstrated a signifi-











































Figure 4 ILT2 expression by T cell populations in melanoma patients
blood cells expressing (A) FoxP3 among CD4+ T cells and ILT2 among (B)
evaluated by flow cytometry in metastatic melanoma patients (n = 4) befortreatment with oncolytic vaccinia virus (P = 0.007;
Figure 5C).
We also evaluated CD8+ Ts cells and found that there
were no differences in these cells at baseline between
responding and non-responding patients (P = 0.127,
Figure 6A). Evaluation of CD8+ILT2+T cells showed a
similar pattern with no overall differences between
responding and non-responding patients pre (P = 0.512)
or post (P = 0.235) treatment (Figure 6B). However,
when we analyzed CD8+FoxP3+ILT2+ T cells we found
a significantly lower frequency of these cells in respond-
ing patients at baseline (P = 0.020) and after treatment
(P = 0.019; Figure 6C) than in non-responding patients.
These data suggest that ILT2 may be useful for identify-
ing a subset of CD8+ suppressor T cells that may be a
predictive biomarker of oncolytic virus immunotherapy
outcome.
Discussion
Oncolytic virus therapy is gaining momentum as a novel
form of immunotherapy for patients with cancer. Vac-
cinia virus has been a highly versatile viral vector and
was initially developed for vaccination of cancer patients
by encoding tumor-associated antigens alone or with T












































Pre Post Pre Post
D
before and after rV-B7.1 treatment. (A-D) Frequency of peripheral
CD4+ T cells, (C) CD8+ T cells, and (D) CD4+FoxP3+ T cells was
e (pre) and after (post) intra-tumoral rV-B7.1 treatment.
Figure 5 ILT2 expression by CD4+ T cell populations in non-responder and responder melanoma patients before and after rV-B7.1
treatment. (A-D) Frequency of peripheral blood cells expressing (A) FoxP3 among CD4+ T cells and ILT2 among (B) CD4+ T cells, and (C) CD4
+FoxP3+ T cells was evaluated by flow cytometry in non-responder (n = 5) and responder (n = 4) metastatic melanoma patients before (pre) and
after (post) intra-tumoral rV-B7.1 treatment.
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stimulatory molecules were generated for use as oncoly-
tic agents wherein the viruses are injected directly into
tumors resulting in a direct oncolytic effect, release of
individual tumor-specific antigens and local expression
of T cell co-stimulatory molecules to enhance the induc-
tion and activation of local T cell responses [3,4]. Specif-
ically, in a series of early phase studies we demonstrated
the safety and initial therapeutic responses of vaccinia
viruses encoding human T cell co-stimulatory molecules
(rV-B7.1 and rV-TRICOM). Other approaches utilizing
modified herpes viruses, native coxsackie viruses and
Newcastle disease viruses have also reported promising
results [1]. The identification of predictive biomarkers is
important for optimizing patient selection for treatment,
monitoring individual immune responses in patientsFigure 6 ILT2 expression by CD8+ T cell populations in non-responde
treatment. (A-D) Frequency of peripheral blood cells expressing (A) FoxP3
+FoxP3+ T cells was evaluated by flow cytometry in non-responder (n = 5)
after (post) intra-tumoral rV-B7.1 treatment.undergoing active treatment, and determining which pa-
tients may achieve clinical responses with continued
therapy. Immunotherapy has been associated with de-
layed kinetics of therapeutic responses, as reported for
the anti-CTLA-4 monoclonal antibody therapy with ipi-
limumab [10], making the discovery of predictive bio-
markers critical for the clinical management of patients
receiving immunotherapy. This is the first report of a
potential biomarker for oncolytic virus immunotherapy,
although the results may have implications for other
forms of immunotherapy as well.
We identified ILT2 as a putative biomarker from a
customized microarray performed on peripheral blood
mononuclear cells exposed to rV-B7 oncolytic virus and
confirmed the marker in a second microarray (Figure 2A)
and quantitative PCR (Figure 2B) analysis from finer and responder melanoma patients before and after rV-B7.1
among CD8+ T cells and ILT2 among (B) CD8+ T cells, and (C) CD8
and responder (n = 4) metastatic melanoma patients before (pre) and
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the oncolytic rV-B7 and rV-TRICOM viruses. ILT2 is an
immune regulatory receptor that contains an extracellu-
lar Ig-like domain, is responsible for ligand binding at
the cell surface, and has a long cytoplasmic tail contain-
ing immunoreceptor tyrosine inhibitory motif (ITIM),
which recruits inhibitory phosphatases and mediates in-
hibition of cell activation intracellularly [11-14]. ILT2 is
expressed on T cells and antigen-presenting cells where
it inhibits T cell receptor signaling and T cell activation
and proliferation. ILT2 interacts with HLA-G, expressed
on antigen-presenting cells and tumor cells, such as mel-
anoma [15-18]. ILT2 functions to dampen T cell re-
sponses and may contribute to T cell tolerance in cancer,
although the role of ILT2 in oncology has not been well
studied. T cell co-inhibitory molecules, such as CTLA-4
and PD-1, have been validated through numerous pre-
clinical and clinical trials, as critical mediators of tumor
immune suppression [19]. We speculate that ILT2 may
represent another T cell co-inhibitory receptor with
similar activity in patients with cancer.
In this study, we found that ILT2 could be detected on
both CD4+ and CD8+ T cells in patients with metastatic
melanoma and that ILT2 correlated with FoxP3 expres-
sion. While this further supports the potential role of
ILT2 in inhibiting anti-tumor immunity, this association
needs to be further validated in larger, prospective trials.
Whereas FoxP3 is an intracellular protein, ILT2 is an
extracellular membrane protein that is easily detected by
flow cytometry without disruption of the cell membrane.
Importantly, we observed a significant increase in ILT2-
expressing T cells in melanoma patients compared to
healthy donors (Figure 3) and this is similar to previous
reports of increased frequency of Tregs in patients with
melanoma [9].
We did not see significant differences in ILT2-
expressing T cell or Treg populations following oncolytic
vaccinia immunotherapy (Figure 4) but we did find that
ILT2-expressing T cells were correlated with clinical re-
sponse as defined through local gene expression in the
tumor microenvironment (Figure 2B) and in peripheral
blood T cell staining (Figures 5 and 6). These data sug-
gest that oncolytic virus therapy may not be changing
the T cell responses but rather ILT2 expression may be a
more general biomarker of patients predisposed to re-
spond to immunotherapy. This effect was seen in both
CD4+ and CD8+ T cells, and a low frequency of
CD8+ILT2+ T cells appeared to be highly predictive of
clinical response even at baseline (Figure 6C).
Conclusions
We have identified ILT2 as a potential biomarker of clin-
ical response in melanoma patients treated with oncoly-
tic vaccinia virus immunotherapy. Patients with adecrease in CD4+ILT2+ T cells, CD4+FoxP3+ILT2+ T
cells, and CD8+FoxP3+ILT2+ T cells following treatment
had an increased likelihood of responding to oncolytic im-
munotherapy. While this study identified ILT2 as a puta-
tive biomarker, further validation of ILT2 will require
evaluation in larger, prospective clinical trials. Our data
also suggests that decreases in ILT2-expressing T cells
were predictive of clinical response but not of exposure to
oncolytic viruses and this may have implications for ILT2
as a more general predictive biomarker of response to
tumor immunotherapy. Finally, the general role of ILT2 as
a T cell inhibitor has not been widely explored but it is
possible that ILT2 may be a novel T cell checkpoint target




The patient characteristics and clinical trial results asso-
ciated with the patient samples used here have been pre-
viously reported [3,4]. These clinical trials were
approved by the Institutional Review Board of Columbia
University, NY. Briefly, patients with metastatic melan-
oma and accessible, measurable lesions received three
intra-tumoral (IT) injections every four weeks. In one
phase I clinical trial, 12 patients with metastatic melan-
oma and accessible lesions for injection were treated in
a dose escalation manner with two different concentra-
tions of rV-B7.1 (4.26 × 107 and 4.26 × 108 plaque-
forming units [PFUs]). In a second phase I clinical trial,
13 patients with accessible, metastatic melanoma were
treated in a dose escalation manner with rV-TRICOM
(5.1 × 106 and 5.1 × 108 PFUs). Prior to each injection
and two weeks after injection, peripheral blood was col-
lected for serum and T cell assays. Four weeks after the
third injection, patients underwent imaging studies to
assess disease status and fine needle aspiration of
injected lesions was performed on those patients who
voluntarily consented. Those patients without objective
disease progression and who still met eligibility criteria
were offered booster vaccinations following the same
schema. Written informed consent was obtained from
all patients and the trial was conducted in accordance
with the Declaration of Helsinki. Six healthy donors
were solicited from local institutions and had peripheral
blood collected after providing written informed
consent.
Gene expression profiling
To compare gene expression profiles between re-
sponders (n = 2) and non-responders (n = 3), tumor fine
needle aspirates (FNAs) were obtained. RNA was ex-
tracted from the FNAs for microarray testing. PBMCs
from six healthy donors were treated with rV-B7.1 and
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fore and 12 hours after treatment. The 32x24x23 (17,000
spot) human cDNA microarray was prepared in the Im-
munogenetics Section of the Department of Transfusion
Medicine, Clinical Center, National Institutes of Health
[20,21]. Clones used for the printing of 17 k cDNA array
included a combination from a RG_HsKG_031901 7 k
clone set and 10,000 clones from the RG_Hs_seq_-
ver_070700 40 k clone set (Research Genetics, Hunts-
ville, AL), which were designed to cover genes relevant
to immune function. The cDNA clones include 12,072
uniquely named genes, 875 duplicates of named gene
and the remainder consists of expression sequence tags.
Reproducibility of the data set was assessed by a matrix
of repeated experiments. A level of concordance of gene
expression ≥ 95% was met in all experiments. Analysis of
array data was based on Cluster and Treeview programs
from the Stanford Genome Analysis Group Software
package (Stanford, CA).
Flow cytometry analysis
To determine the frequency of T cells and regulatory/
suppressor T cells expressing ILT2, FITC-CD4, PE-CD8,
PECY5-CD3, APC-ILT2 and eFluor450-Foxp3 antibodies
(Ebioscience, San Diego, CA) were used. Data acquisi-
tion and analysis were performed using a FACSCantoII
flow cytometer (BD Bioscience, San Jose, CA) and
FlowJo software (TreeStar, Ashland, OR).
Statistical analysis
Results are expressed as mean ± standard deviation (SD)
or range when appropriate. A student t test was used in
comparisons of two groups. One-way analysis of vari-
ance (ANOVA) was applied (with Bonferonni correction)
when comparing three or more groups. Differential gene
expression between pre- and post-rV-B7.1 treatment
samples was analyzed by two-tailed, paired t test. Statis-
tical analyses were performed using Prism 5 software
(Gaphpad Software, Inc., La Jolla, CA). Values of
P < 0.05 were considered statistically significant.
Additional files
Additional file 1: Table S1. Up-regulated genes in PBMCs after rV-B7.1
treatment. Healthy donor (n = 6) PBMCs were treated with rV-B7.1 vaccine
for 12 hours and gene expression profiles were analyzed using a
customized 32x24x23 (~17,000 spot) human cDNA microarray.
Additional file 2: Table S2. Down-regulated genes in PBMCs after rV-
B7.1 treatment. Healthy donor (n = 6) PBMCs were treated with rV-B7.1
vaccine for 12 hours and gene expression profiles were analyzed using a
customized 32x24x23 (~17,000 spot) human cDNA microarray.
Additional file 3: Table S3. Up-regulated and down-regulated genes in
the tumor microenvironment after rV-B7.1 treatment. Gene expression
profiles from metastatic melanoma lesions were obtained from fine
needle aspiration (FNA) samples (n = 5) before (pre) and after (post) rV-
B7.1 vaccination and analyzed using a customized 32x24x23 (~17,000spot) human cDNA microarray. Results pre and post oncolytic vaccine
treatment are further shown for responders (n = 2; 103 SD and 104 PR)
and non-responders (n = 3; 105 PD, 107 PD, 109 PD).
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